BPI-43487 / Betta Pharma - LARVOL DELTA

A validated UHPLC-MS/MS method for determination of BPI-43487 and its metabolite BPI-43739 in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumors. (PubMed, Bioanalysis) - "This method was further successfully applied to a pharmacokinetic study of BPI-43487 capsules in Chinese patients with advanced solid tumors. http://www.chinadrugtrials.org.cn is CTR20210565)."

Journal • PK/PD data • Hepatocellular Cancer • Oncology • Solid Tumor • FGFR4

Betta’s FGFR4 inhibitor approved for Phase I study in China (GBI Health) - "China-based Betta Pharmaceuticals Co., Ltd (300558.SZ) has announced a clinical trial nod from the National Medical Products Administration to initiate a Phase I clinical study for their drug candidate BPI-43487 in China. BPI-43487 is a potent and highly selective fibroblast growth factor receptor 4 (FGFR4) covalent non-reversible small molecule inhibitor under development to treat hepatocellular carcinoma and cholangiocarcinoma among other solid tumors with fibroblast growth factor 19 expansion."

Non-US regulatory • Cholangiocarcinoma • Hepatocellular Cancer • Oncology • Solid Tumor